Recent advances in technology supporting biopharmaceutical production from mammalian cells
Identifieur interne : 001377 ( Main/Exploration ); précédent : 001376; suivant : 001378Recent advances in technology supporting biopharmaceutical production from mammalian cells
Auteurs : M. Butler [Canada] ; A. Meneses-Acosta [Mexique]Source :
- Applied Microbiology and Biotechnology [ 0175-7598 ] ; 2012-11-01.
English descriptors
- KwdEn :
Abstract
Abstract: The demand for production of glycoproteins from mammalian cell culture continues with an increased number of approvals as biopharmaceuticals for the treatment of unmet medical needs. This is particularly the case for humanized monoclonal antibodies which are the largest and fastest growing class of therapeutic pharmaceuticals. This demand has fostered efforts to improve the efficiency of production as well as to address the quality of the final product. Chinese hamster ovary cells are the predominant hosts for stable transfection and high efficiency production on a large scale. Specific productivity of recombinant glycoproteins from these cells can be expected to be above 50 pg/cell/day giving rise to culture systems with titers of around 5 g/L if appropriate fed-batch systems are employed. Cell engineering can delay the onset of programmed cell death to ensure prolonged maintenance of productive viable cells. The clinical efficacy and quality of the final product can be improved by strategic metabolic engineering. The best example of this is the targeted production of afucosylated antibodies with enhanced antibody-dependent cell cytotoxicity, an important function for use in cancer therapies. The development of culture media from non-animal sources continues and is important to ensure products of consistent quality and without the potential danger of contamination. Process efficiencies may also be improved by employing disposable bioreactors with the associated minimization of downtime. Finally, advances in downstream processing are needed to handle the increased supply of product from the bioreactor but maintaining the high purity demanded of these biopharmaceuticals.
Url:
DOI: 10.1007/s00253-012-4451-z
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000973
- to stream Istex, to step Curation: 000967
- to stream Istex, to step Checkpoint: 000438
- to stream Main, to step Merge: 001379
- to stream Main, to step Curation: 001377
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent advances in technology supporting biopharmaceutical production from mammalian cells</title><author><name sortKey="Butler, M" sort="Butler, M" uniqKey="Butler M" first="M." last="Butler">M. Butler</name></author><author><name sortKey="Meneses Acosta, A" sort="Meneses Acosta, A" uniqKey="Meneses Acosta A" first="A." last="Meneses-Acosta">A. Meneses-Acosta</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4811CFB8906FE0C8DFDE9AAC9AEEDE0B042075F7</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1007/s00253-012-4451-z</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-XTND2DK0-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000973</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000973</idno><idno type="wicri:Area/Istex/Curation">000967</idno><idno type="wicri:Area/Istex/Checkpoint">000438</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000438</idno><idno type="wicri:doubleKey">0175-7598:2012:Butler M:recent:advances:in</idno><idno type="wicri:Area/Main/Merge">001379</idno><idno type="wicri:Area/Main/Curation">001377</idno><idno type="wicri:Area/Main/Exploration">001377</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Recent advances in technology supporting biopharmaceutical production from mammalian cells</title><author><name sortKey="Butler, M" sort="Butler, M" uniqKey="Butler M" first="M." last="Butler">M. Butler</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Microbiology, University of Manitoba, R3T 2N2, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="Meneses Acosta, A" sort="Meneses Acosta, A" uniqKey="Meneses Acosta A" first="A." last="Meneses-Acosta">A. Meneses-Acosta</name><affiliation wicri:level="1"><country xml:lang="fr">Mexique</country><wicri:regionArea>Pharmaceutical Biotechnology Lab., Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Morelos</wicri:regionArea><wicri:noRegion>Morelos</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Mexique</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Applied Microbiology and Biotechnology</title><title level="j" type="abbrev">Appl Microbiol Biotechnol</title><idno type="ISSN">0175-7598</idno><idno type="eISSN">1432-0614</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2012-11-01">2012-11-01</date><biblScope unit="volume">96</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="885">885</biblScope><biblScope unit="page" to="894">894</biblScope></imprint><idno type="ISSN">0175-7598</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0175-7598</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies</term><term>Apoptosis</term><term>Biopharmaceuticals</term><term>CHO cells</term><term>Glycosylation</term><term>Vaccines</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The demand for production of glycoproteins from mammalian cell culture continues with an increased number of approvals as biopharmaceuticals for the treatment of unmet medical needs. This is particularly the case for humanized monoclonal antibodies which are the largest and fastest growing class of therapeutic pharmaceuticals. This demand has fostered efforts to improve the efficiency of production as well as to address the quality of the final product. Chinese hamster ovary cells are the predominant hosts for stable transfection and high efficiency production on a large scale. Specific productivity of recombinant glycoproteins from these cells can be expected to be above 50 pg/cell/day giving rise to culture systems with titers of around 5 g/L if appropriate fed-batch systems are employed. Cell engineering can delay the onset of programmed cell death to ensure prolonged maintenance of productive viable cells. The clinical efficacy and quality of the final product can be improved by strategic metabolic engineering. The best example of this is the targeted production of afucosylated antibodies with enhanced antibody-dependent cell cytotoxicity, an important function for use in cancer therapies. The development of culture media from non-animal sources continues and is important to ensure products of consistent quality and without the potential danger of contamination. Process efficiencies may also be improved by employing disposable bioreactors with the associated minimization of downtime. Finally, advances in downstream processing are needed to handle the increased supply of product from the bioreactor but maintaining the high purity demanded of these biopharmaceuticals.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Mexique</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Canada"><region name="Manitoba"><name sortKey="Butler, M" sort="Butler, M" uniqKey="Butler M" first="M." last="Butler">M. Butler</name></region><name sortKey="Butler, M" sort="Butler, M" uniqKey="Butler M" first="M." last="Butler">M. Butler</name></country><country name="Mexique"><noRegion><name sortKey="Meneses Acosta, A" sort="Meneses Acosta, A" uniqKey="Meneses Acosta A" first="A." last="Meneses-Acosta">A. Meneses-Acosta</name></noRegion><name sortKey="Meneses Acosta, A" sort="Meneses Acosta, A" uniqKey="Meneses Acosta A" first="A." last="Meneses-Acosta">A. Meneses-Acosta</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001377 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001377 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4811CFB8906FE0C8DFDE9AAC9AEEDE0B042075F7
|texte= Recent advances in technology supporting biopharmaceutical production from mammalian cells
}}
| This area was generated with Dilib version V0.6.33. |  |